RV.Net Open Roads Forum: Around the Campfire: 2019–2022 CORONAVIRUS PANDEMIC POSTINGS

RV Blog

  |  

RV Sales

  |  

Campgrounds

  |  

RV Parks

  |  

RV Club

  |  

RV Buyers Guide

  |  

Roadside Assistance

  |  

Extended Service Plan

  |  

RV Travel Assistance

  |  

RV Credit Card

  |  

RV Loans

Open Roads Forum Already a member? Login here.   If not, Register Today!  |  Help

Newest  |  Active  |  Popular  |  RVing FAQ Forum Rules  |  Forum Posting Help and Support  |  Contact  

Search:   Advanced Search

Search only in Around the Campfire

Open Roads Forum  >  Around the Campfire  >  General Topics

 > 2019–2022 CORONAVIRUS PANDEMIC POSTINGS

Reply to Topic  |  Subscribe  |  Print Page  |  Post New Topic  | 
Page of 146  
Prev  |  Next
Sponsored By:
BCSnob

Middletown, MD

Senior Member

Joined: 02/23/2002

View Profile



Posted: 08/23/21 07:59am Link  |  Quote  |  Print  |  Notify Moderator

FDA Approves First COVID-19 Vaccine

Pfizer’s vaccine has full fda approval

Deb and Ed M

SW MI & Space Coast, FL USA

Senior Member

Joined: 06/07/2004

View Profile



Posted: 08/23/21 12:40pm Link  |  Quote  |  Print  |  Notify Moderator



I copied this from the study, because isn't this pretty much our worst fear (so far?)? A variant that knows how to hide from our immune system plus the treatment to lessen its impact?

"The ability of the lambda variant to escape the immune response is likely achieved by two possible routes. One explanation is the shortening of antibody binding sites on the loops of the spike protein, while the other is by changing the level of glycosylation upwards. These factors have already been found to occur during viral transmission protect the virus from antibody recognition.

In another recent preprint study, a seven-residue deletion at the NTD of the lambda variant was observed. This deletion could make this variant resistant to antiviral immunity, thus agreeing with the findings of the current study."

Deb and Ed M

SW MI & Space Coast, FL USA

Senior Member

Joined: 06/07/2004

View Profile



Posted: 08/23/21 12:45pm Link  |  Quote  |  Print  |  Notify Moderator

I love the covidactnow.org website! Michigan is slowly on the rise; but I predict it will start to climb quickly once we (and the folks in Wisconsin/Minnesota, etc) start spending more time indoors. In MY area of the state, the resistance to the vaccine or masking is fierce. Delta is going to love it here :-(

BCSnob

Middletown, MD

Senior Member

Joined: 02/23/2002

View Profile



Posted: 08/23/21 02:59pm Link  |  Quote  |  Print  |  Notify Moderator

If you like computer modeling studies read this one.

Modeling Coronavirus Spike Protein Dynamics: Implications for Immunogenicity and Immune Escape
BioRxiv preprint

BCSnob

Middletown, MD

Senior Member

Joined: 02/23/2002

View Profile



Posted: 08/23/21 03:18pm Link  |  Quote  |  Print  |  Notify Moderator

Two preprints where the patient serums (neutralizing antibodies produced by vaccination and/or previous infection) were tested against several variants including lambda. These studies found similar neutralization of lambda and delta with these patient serums.

Quote:

SARS-CoV-2 Lambda Variant Remains Susceptible to Neutralization by mRNA Vaccine-elicited Antibodies and Convalescent Serum
bioRxiv Preprint 3 July 2021

Virus with the lambda spike protein, like several VOC variant spike proteins showed a partial resistance to neutralization by vaccine-elicited antibodies and convalescent sera; however the average 3-fold decrease in neutralizing titer against the variant is not likely to cause a significant loss of protection against infection as the average neutralization IC50 titer by the sera of BNT162b2 and mRNA-1273 vaccinated individuals was about 1:600, a titer that is above that in the sera of individuals who recovered from infection with the parental D614G virus. A small fraction of vaccinated individuals had serum antibody titers less than average but whether this will lead to reduced protection from variant infection will need to be determined in epidemiological studies.


Quote:

Comparison of Neutralizing Antibody Titers Elicited by mRNA and Adenoviral Vector Vaccine against SARS-CoV-2 Variants
bioRxiv Preprint 6 Aug 2021


Several reports have shown partial resistance of SARS-CoV-2 VOCs to vaccine-elicited antibodies4-11. The data shown here extend those findings to the Delta plus and Lambda variants. Delta plus and Lambda, VOIs, both displayed a degree of resistance to mRNA vaccine-elicited antibodies similar to that of the Beta and Delta variants. In sera collected ~3 months post-second immunization, BNT162b2 and mRNA-1273 mRNA vaccine-elicited antibodies neutralized the variants with a modest 3-fold average decrease in titer resulting in an average IC50 of about 1:600, a titer that is greater than that of convalescent sera and likely, in combination with post-vaccination T-and B-cell memory responses, to provide durable protection.


MEXICOWANDERER

las peñas, michoacan, mexico

Senior Member

Joined: 06/01/2007

View Profile


Offline
Posted: 08/23/21 06:10pm Link  |  Quote  |  Print  |  Notify Moderator

The macro defense combination of adenovirus vaccine, mRNA vaccine, then subsequent natural infection, generates an impressively potent final immune response to COVID-19

What depresses me are the billions of active Petri Dishes, allowing a near infinite array of mutations to emerge. The idea that masking is "failed filtering" rather than its true purpose as a distance limiting muffler of contaminated breath. And utter ignorance of how an equal number of people can contaminate a confined indoor space dozens of times as intense as an outdoor setting.

BCSnob

Middletown, MD

Senior Member

Joined: 02/23/2002

View Profile



Posted: 08/24/21 06:20am Link  |  Quote  |  Print  |  Notify Moderator

Preprint posted yesterday

mRNA Vaccination Induces Durable Immune Memory to SARS-CoV-2 with Continued Evolution to Variants of Concern
bioRxiv Preprint 23 Aug 2021

Quote:

ABSTRACT
SARS-CoV-2 mRNA vaccines have shown remarkable efficacy, especially in preventing severe illness and hospitalization. However, the emergence of several variants of concern and reports of declining antibody levels have raised uncertainty about the durability of immune memory following vaccination. In this study, we longitudinally profiled both antibody and cellular immune responses in SARS-CoV-2 naïve and recovered individuals from pre-vaccine baseline to 6 months post mRNA vaccination. Antibody and neutralizing titers decayed from peak levels but remained detectable in all subjects at 6 months post-vaccination. Functional memory B cell responses, including those specific for the receptor binding domain (RBD) of the Alpha (B.1.1.7), Beta (B.1.351), and Delta (B.1.617.2) variants, were also efficiently generated by mRNA vaccination and continued to increase in frequency between 3 and 6 months post-vaccination. Notably, most memory B cells induced by mRNA vaccines were capable of cross-binding variants of concern, and B cell receptor sequencing revealed significantly more hypermutation in these RBD variant binding clones compared to clones that exclusively bound wild-type RBD. Moreover, the percent of variant cross-binding memory B cells was higher in vaccinees than individuals who recovered from mild COVID-19. mRNA vaccination also generated antigen-specific CD8+ T cells and durable memory CD4+ T cells in most individuals, with early CD4+ T cell responses correlating with humoral immunity at later timepoints. These findings demonstrate robust, multi-component humoral and cellular immune memory to SARS-CoV-2 and current variants of concern for at least 6 months after mRNA vaccination. Finally, we observed that boosting of pre-existing immunity with mRNA vaccination in SARS-CoV-2 recovered individuals primarily increased antibody responses in the short-term without significantly altering antibody decay rates or long-term B and T cell memory. Together, this study provides insights into the generation and evolution of vaccine induced immunity to SARS-CoV-2, including variants of concern, and has implications for future booster strategies.


  • Measured antibody levels declined overtime past vaccination
  • Memory cell responses remained and became more diverse in cross reactivity to other variants then the wildtype which was used to develop the vaccine


* This post was edited 08/24/21 06:48am by BCSnob *

Deb and Ed M

SW MI & Space Coast, FL USA

Senior Member

Joined: 06/07/2004

View Profile



Posted: 08/24/21 08:56am Link  |  Quote  |  Print  |  Notify Moderator

Mark - thank you for once again injecting a bit of sunshine into what often seems like a bleak future :-) I live in an area heavy with "anti" sentiment - the VOCs will have fertile breeding/mutating grounds here...LOL!

BCSnob

Middletown, MD

Senior Member

Joined: 02/23/2002

View Profile



Posted: 08/25/21 07:28pm Link  |  Quote  |  Print  |  Notify Moderator

SARS-CoV-2 susceptibility and ACE2 gene variations within diverse ethnic backgrounds
MedRxiv preprint 25Aug2021
Quote:

genetic variants in ACE2 may inform risk stratification of COVID-19 patients and could partially explain the differences in disease susceptibility and severity among different ethnic groups.

The human genetics associated with the ACE2 receptor were correlated to COVID-19 infections and severity of the infections.

Quote:

We identified a splice site variant (rs2285666) associated with increased ACE2 expression with an overrepresentation in SARS-CoV-2 positive patients relative to 100KGP controls

Quote:

The eQTL rs12006793 had the largest effect size (d = 0.91), which decreases ACE2 expression and is more prevalent in controls, thus potentially reducing risk of COVID-19.

Quote:

three variants (p.K26R, p.H378R, p.Y515N) alter receptor affinity for the viral Spike (S) protein. Variants p.K26R and p.N720D are more prevalent in the European population


Sars-cov-2 spike binding to the ace2 receptor has two genetic components; the genetic variants of the virus and the genetic variants associated with the ace2 receptor.

charlestonsouthern

Summerville, SC

Senior Member

Joined: 04/16/2009

View Profile



Good Sam RV Club Member

Offline
Posted: 08/26/21 09:50pm Link  |  Quote  |  Print  |  Notify Moderator

BCSnob, we really appreciate all the sources and backup information you give us on this forum; I used it in my neighborhood for reference to a neighbor when she was having a hard time making a decision as to getting vaccines for her and her family; her whole family 12 and over got the vaccines; I know you are blushing now (Ha!); but you do save lives. And Moderator, thank you for starting this forum.

By the way, on the RVing in Mexico forum in answer to a Covid discussion, I read your link regarding smallpox in this country before it was erased. So it wasn't a total loss.

Reply to Topic  |  Subscribe  |  Print Page  |  Post New Topic  | 
Page of 146  
Prev  |  Next

Open Roads Forum  >  Around the Campfire  >  General Topics

 > 2019–2022 CORONAVIRUS PANDEMIC POSTINGS
Search:   Advanced Search

Search only in Around the Campfire


New posts No new posts
Closed, new posts Closed, no new posts
Moved, new posts Moved, no new posts

Adjust text size:




© 2021 CWI, Inc. © 2021 Good Sam Enterprises, LLC. All Rights Reserved.